Boston, MA – According to filings with the U.S. Securities and Exchange Commission, Sherlock Biosciences is raising $80,000,013.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Bryan Dechairo played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Sherlock Biosciences
Sherlock Biosciences aims to disrupt molecular diagnostics with better, faster, affordable tests. With our unique Engineering Biology platforms, we are on the cusp of solving challenges ranging from faster pathogen detection and simpler testing for cancer to improved food safety. We envision a world where our products will enable users to make more effective decisions in any environment, whether in hospitals, industrial settings, the developing world, or at home. Our team and founders include Engineering Biology pioneers with world-leading expertise in CRISPR and Synthetic Biology, diagnostic industry veterans, and disease-area authorities. Together, they provide an unparalleled set of capabilities that are transforming molecular diagnostics in clinical and non-clinical settings.

To learn more about Sherlock Biosciences, visit http://sherlock.bio/

Contact:
Bryan Dechairo, President and Chief Executive Officer
617-612-8209
bryan@sherlock.bio
https://www.linkedin.com/in/bryandechairo/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved